Exacerbation information | No of patients (%, N=76) |
Experienced psoriasis flare | 43 (57) |
Cutaneous involvement | 39 (51) |
Extracutaneous manifestations | 7 (9) |
Arthritis | 6 (8) |
Iritis | 1 (1) |
Time (days) from ICI initiation to flare, median (range) | 43.5 (1–725) |
Worst grade of psoriasis flare | |
1 | 15 (20) |
2 | 21 (28) |
3 | 6 (8) |
4 | 1 (1) |
Treatment for psoriasis flare | |
Acitretin* | 3 (4) |
Methotrexate† | 1 (1) |
Prednisone‡ | 9 (12) |
Small molecule inhibitors§ | 3 (4) |
Topicals only | 23 (30) |
Total patients with other irAE | 45 (59) |
Colitis (including diarrhea) | 16 (21) |
Skin (excluding psoriasis) | 13 (17) |
Endocrine | 11 (14) |
Liver | 11 (14) |
Joint | 6 (8) |
Lung | 3 (4) |
Mucositis/oral cavity | 2 (3) |
Other | 3 (34) |
Grade 3 or 4 other irAE | 17 (22) |
Colitis (including diarrhea) | 7 (9) |
Skin (excluding psoriasis) | 2 (3) |
Endocrine | 0 |
Liver | 5 (7) |
Joint | 1 (1) |
Lung | 2 (3) |
Mucositis/oral cavity | 0 |
Other | 0 |
Grade 3 or 4 other irAE per immunotherapy class | |
Anti-PD-1/PD-L1 | 8 (16) |
Anti-CTLA-4 | 3 (37.5) |
Combination | 6 (35) |
Reason for immunotherapy discontinuation | |
Treatment completion/response/patient decision | 17 (22) |
Psoriasis flare | 5 (7) |
Other irAE | 22 (29) |
Disease progression | 22 (29) |
Other (including ongoing treatment) | 10 (13) |
*Two patients treated with topicals.
†One patient treated with prednisone/topicals.
‡Three patients treated with topicals, one with acitretin, one with small molecule inhibitor/topicals.
§One patient treated with acitretin/topicals, one with topicals.
ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events.